Breakthrough in Pediatric Asthma Care: Vapotherm's HVNI Reduces Hospital Stay and Escalation Needs, Reveals ERS 2023 Study

Benzinga ·  09/25 18:47

Vapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced the presentation of an Investigator-initiated clinical trial, "High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial" at the European Respiratory Society International Congress 2023. The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs. Hector Rojas-Anaya and Paul

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write first comment